Douglas Reznick, MD
Hematology & Oncology · Aurora, CONPI 1124002456
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $210,179 of the $293,650 with a category attached, or 71.6%. AstraZeneca accounts for 88.1% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $132,357 and has fallen 78.6% since, to $28,315 in 2025. Among hematology & oncology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $1045.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$259K
- E.r. Squibb & Sons, L.L.C.$15K
- Merck$8K
- Sun Pharmaceutical Industries Inc.$7K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Astrazeneca UK Limited$1K
- plus $950 from 16 others
Across 1 payment — averaging $9719.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$10K
What the payments were for
- Consulting fees$54,84219%
- Speaking & faculty fees$210,17972%
- Travel & lodging$22,0558%
- Food & beverage$6,5362%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 218 | $258,648 |
| E.r. Squibb & Sons, L.L.C. | 18 | $15,290 |
| Merck | 11 | $8,354 |
| Sun Pharmaceutical Industries Inc. | 9 | $7,396 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,625 |
| Astrazeneca UK Limited | 1 | $1,388 |
| Johnson & Johnson | 2 | $268 |
| Tactile Systems Technology Inc | 2 | $168 |
| Monteris Medical Corporation | 1 | $136 |
| Amgen | 3 | $63 |
| Bristol Myers Squibb | 2 | $43 |
| Tolmar, Inc. | 2 | $41 |
| Exelixis Inc. | 1 | $40 |
| Astellas Pharma US Inc | 1 | $35 |
| Eisai Inc. | 2 | $27 |
| Incyte Corporation | 1 | $22 |
| Pharmaand GmbH | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| AbbVie | 1 | $20 |
| Pfizer | 1 | $18 |
| Novartis | 1 | $16 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$130,500
- IMFINZI$112,241
- OPDIVO$14,254
- KEYTRUDA$8,202
- Unloxcyt$7,265
- ALUNBRIG$1,625
- Monarch Platform$268
- Flexitouch Plus$154
- Entre Plus$154
- Neuroblate$136
- LYNPARZA$115
How this compares
$293,650 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrazatiAdagrasib | 17 | $311,100 |
| TagrissoOsimertinib Mesylate | 18 | $307,675 |
| MekinistTrametinib Dimethyl Sulfoxide | 18 | $295,477 |
| TabrectaCapmatinib Hydrochloride | 13 | $278,838 |
| EliquisApixaban | 98 | $78,095 |
| ImbruvicaIbrutinib | 12 | $70,245 |
| XareltoRivaroxaban | 54 | $54,328 |
| TirosintLevothyroxine Sodium | 16 | $2,411 |
| Dexamethasone | 53 | $1,238 |
| Liothyronine Sodium | 41 | $1,116 |
| Methylprednisolone | 18 | $977 |
| Levothyroxine Sodium | 126 | $868 |
| Levetiracetam | 24 | $609 |
| Folic Acid | 70 | $552 |
| Gabapentin | 43 | $468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMekinist, Tabrecta | $16 | $574,31531 claims |
| Mirati Therapeutics, Inc.Krazati | $21 | $311,10017 claims |
| AstraZenecaTagrisso | $258,648 | $307,67518 claims |
| PfizerEliquis | $18 | $78,09598 claims |
| Johnson & JohnsonXarelto | $268 | $54,32854 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Aurora
- John BurkeAurora$321K
- Daniel PollyeaAurora$274K
- Sami DiabAurora$134K
- Manali KamdarAurora$129K
- Bradley HaverkosAurora$120K
- Sujatha NallapareddyAurora$112K
- Tomer MarkAurora$96K
- Ara MetjianAurora$89K
- Ryan WeightAurora$65K
- Breelyn WilkyAurora$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.